Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | PTAFR | P25105 | 3/20 | 0.36 |
| ▸ | FTH1 | P02794 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486589 | 0.81 | CYP3A4 (0.35) | CYP3A4PTAFRFTH1CYP2C9CYP2C19 | |
| SCHEMBL9979491 | 0.75 | FNTA (0.33) | CYP3A4FTH1CYP2C9CYP2C19 | |
| SCHEMBL24766475 | 0.74 | TSHR (0.35) | — | |
| SCHEMBL217966 | 0.74 | TSHR (0.35) | — | |
| SCHEMBL13355527 | 0.73 | CYP3A4 (0.39) | CYP3A4PTAFRFTH1CYP2C9CYP2C19 | |
| SCHEMBL9979492 | 0.70 | CYP3A4 (0.38) | CYP3A4PTAFRFTH1CYP2C9CYP2C19 | |
| Michelenolide SCHEMBL31237734 | 0.69 | NLRP3 (0.60) | CYP3A4PTAFRFTH1CYP2C9CYP2C19 | |
| SCHEMBL11177573 | 0.66 | CYP3A4 (0.55) | CYP3A4PTAFRFTH1CYP2C9CYP2C19 | |
| SCHEMBL15484174 | 0.64 | — | — | |
| SCHEMBL13355528 | 0.63 | CYP3A4 (0.39) | CYP3A4PTAFRFTH1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124654-B2 | Derivatives of hypoestoxide and related compounds | IMMUNE MODULATION, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124654-B2 | Derivatives of hypoestoxide and related compounds | IMMUNE MODULATION, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100120853-A1 | Derivatives of Hypoestoxide and Related Compounds | IMMUNE MODULATION, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120853-A1 | Derivatives of Hypoestoxide and Related Compounds | IMMUNE MODULATION, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120853-A1 | Derivatives of Hypoestoxide and Related Compounds | CYP8B1, HAAO, CYP27A1 | CYP3A4 296/4885PTAFR 983/4885FTH1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.